MedTrace Logo

Single Ascending Oral Dose Study to Investigate the Effects of OCT461201 in Healthy Volunteers

NCT06398925 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2024-05-03

No results posted yet for this study

Summary

A study in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of OCT461201. The study included a screening period, a single dose of study treatment or placebo and a follow up period.

Conditions

  • Healthy

Interventions

DRUG

OCT461201 50 mg

Oral capsule

DRUG

OCT461201 100 mg

Oral capsule

DRUG

OCT461201 150 mg

Oral capsule

DRUG

OCT461201 450 mg

Oral capsule

DRUG

Placebo

Placebo capsule

Sponsors & Collaborators

  • Simbec-Orion Group

    collaborator INDUSTRY

  • Oxford Cannabinoid Technologies Holdings PLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-26
Primary Completion
2023-09-25
Completion
2023-09-25

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06398925 on ClinicalTrials.gov